SOURCE: Perma-Fix Environmental Services, Inc.

Perma-Fix Environmental Services, Inc. Logo

August 25, 2014 07:30 ET

Dr. Centofanti to Present Perma-Fix Medical's Tc-99m Production Process at the 8th International Conference on Isotopes and Expo

ATLANTA, GA and WARSAW, POLAND--(Marketwired - August 25, 2014) - Perma-Fix Medical S.A. (WAR: PFM), a subsidiary of Perma-Fix Environmental Services, Inc. (NASDAQ: PESI), and developer of a reliable, cost effective, non-uranium process to produce technetium-99 (Tc-99m), the most widely used medical isotope in the world, announces that Dr. Louis F. Centofanti, of Perma-Fix Medical, will present at the 8th International Conference on Isotopes (8ICI) and Expo today, Monday August 25, 2014 at 1PM Central Time. Dr. Centofanti will provide a detailed discussion of the company's new process to produce Tc-99m which does not involve the use of uranium.

The ICI conferences is organized by the World Council on Isotopes and hosted by the American Nuclear Society. The conference highlights the importance of nuclear science, medicine and technology in advancing human health and protection of the environment. Delegates from around the world-nuclear and medical physicists, radiochemists, engineers, material scientists, physicians, health physicists and specialists in non-proliferation-will come together in Chicago, Illinois, to discuss current and future research in the field of isotopes. The conference will build on past conferences by continuing a multifaceted interdisciplinary exchange between the developers and producers of isotopes, and the researchers who develop and apply isotopes in medicine, industry, agriculture, national security and other fields.

Dr. Louis F. Centofanti, CEO of Perma-Fix Medical, commented, "We are honored to present at this important international conference. We look forward to discussing our technology with industry leaders, including how our process can improve the supply chain and address prevailing concerns about supply shortages for Tc-99m. Importantly, our process does not use uranium and can be performed in most standard commercial or research reactors. We continue moving forward with our plans to commercialize the technology in both the U.S. and Europe and look forward to announcing additional milestones in the near future."

About Perma-Fix Medical
Perma-Fix Medical was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors.

Please visit us on the World Wide Web at http://www.medical-isotope.com.

Contact Information

  • Contacts:
    David K. Waldman
    Crescendo Communications Europe S.A.
    Tel : +1-212-671-1021
    Email : pfm@crescendo-ir.com